SomaLogic Inc. today announced the appointment of Jason Cleveland, Ph.D. as the company’s chief technology officer. In this role, Dr. Cleveland will drive technological innovations that will bring the SomaScan® proteomics platform to patients around the world.
SomaLogic Inc. announced today the appointments of Angela Bakker Lee, Ph.D. as executive vice president for healthcare markets, Tracy Hervey, MBA as executive vice president for life sciences markets and David McGovern, MBA as senior vice president of marketing. In these roles, Dr. Bakker Lee, Ms. Hervey and Mr. McGovern will drive business development and marketing efforts for SomaLogic’s proprietary protein measurement technology and growing portfolio of protein-based health information products.
SomaLogic, Inc. announced today that it added $81M to its current funding round with investments from a number of additional investors, for a total Series A raise of $214M. The funds raised in this round will facilitate improving, expanding and commercializing SomaLogic’s world-leading proteomic products in both the clinical and life science markets.
An international consortium led by Medical Research Council researchers in the UK working with SomaLogic performed the largest genetic discovery of host proteins involved in SARS-CoV-2 infection or severe COVID-19. The results are being shared via an open access platform to help investigators around the world prioritize protein targets for new or repurposed drugs to treat COVID-19. The information may also help medical researchers identify patients who are more likely to develop a serious case of COVID-19.
FonesLife Corporation, a subsidiary of NEC Solution Innovators, Ltd. of Japan, announced today that they will begin offering blood-based health tests built on the SomaLogic SomaScan® Platform to consumers in Japan. The tests, which deliver health-management information based on large-scale measurements of an individual’s blood proteins, are expected to help assess health and promote wellness in Japan’s rapidly aging population.
SomaLogic, Inc., global leader in proteomic discovery and applications transforming biomedical discovery and clinical diagnostics, announced today that the Company has successfully closed an Initial Series A capital raise of $121 Million. The Company anticipates that additional closings will occur within the next 90 days.
SomaLogic, Inc. announced today an agreement with the US Food and Drug Administration (FDA)’s Division of Applied Regulatory Science to evaluate the utility of large-scale analysis of proteins (proteomics) for the identification of biomarkers that may be useful in demonstrating biosimilarity of a proposed biosimilar to a reference biologic.
SomaLogic, Inc. announced today that a collaborative project between SomaLogic scientists and academic researchers has received a $1 million dollar Phase 1 grant from the National Science Foundation Convergence Accelerator program. The team will apply recent advances in quantum sensing to improve methods for proteomic screening.
On December 5, 40 special mice were launched inside a Dragon capsule on a new Falcon 9 booster rocket from Cape Canaveral Air Force Station, headed toward the International Space Station for a 33-day mission. The SomaScan® Assay was used to measure proteomic changes in the mice after their spaceflight and revealed certain biochemical pathways that can be blocked to protect against both muscle and bone loss.
SomaLogic announced today that its United States clinical laboratory (CLIA laboratory) has been re-accredited by the College of American Pathologists (CAP). The successful renewal of CAP accreditation is based on the results of a recent on-site inspection designed to ensure the highest laboratory standards.